News

Bristol-Myers Squibb and ZymoGenetics have released final results from phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naive hepatitis C virus (HCV) patients.

Quintiles has entered into a strategic alliance with Eisai, to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts

Bristol-Myers Squibb has reported 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis. According to the data Baraclude demonstrated greater viral suppression

Gilead Sciences has presented its three-year open label data from two pivotal phase III clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread

Amylin Pharmaceuticals (Amylin) and Eli Lilly have reported that the FDA has approved an expanded indication for Byetta (exenatide) injection. Byetta is now approved for use as a

Eli Lilly and Company (Lilly) has opened a new biotechnology center on the West Coast to discover and develop more biotechnology medicines. The Lilly Biotechnology Center – San

ExonHit has presented clinical data on the validation set ‘Alzheimer patients versus healthy controls’ for AclarusDx, its blood-based diagnostic test for the detection of Alzheimer’s disease (AD). This

Warner Chilcott has completed the acquisition of The Procter & Gamble pharmaceutical business(P&G). The acquisition is expected to complement Warner Chilcott’s existing presence in women’s health care and

Eisai announced preliminary results from a recently completed phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic